Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)
Oncology·MeSH: Hearing Loss
1 drug in development·1 company·0 clinical trials
Drug Pipeline by Phase
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| db-oto | REGENERON PHARMACEUTICALS, INC. (REGN) |
Deep-dive into Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis